Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PMM2 | O15305 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2981956 | 0.93 | RECQL (0.48) | RECQLHCAR1P2RX7MEN1KMT2A | |
| SCHEMBL13664823 | 0.82 | SLC6A2 (0.53) | RECQLHCAR1P2RX7MEN1KMT2A | |
| SCHEMBL13664745 | 0.79 | SLC6A2 (0.55) | RECQLHCAR1P2RX7MEN1KMT2A | |
| SCHEMBL1814949 | 0.68 | ADRB1 (0.56) | P2RX7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15761176 | 0.68 | RECQL (0.45) | RECQLHCAR1P2RX7GAAALOX15 | |
| SCHEMBL24473740 | 0.68 | MAPT (0.68) | RECQLMEN1KMT2AGAAALOX15 | |
| SCHEMBL30505324 | 0.68 | MAPT (0.68) | RECQLMEN1KMT2AGAAALOX15 | |
| SCHEMBL1077363 | 0.67 | ADRB1 (0.70) | SLC6A2 | |
| SCHEMBL3658673 | 0.67 | P2RX7 (0.42) | P2RX7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30910322 | 0.67 | NPC1 (0.54) | RECQLP2RX7MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786157-B2 | OXO-imidazolidines as modulators of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1931348-A4 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | RECQL 3463/4885HCAR1 13/4885P2RX7 597/4885 |
| US-20080269280-A1 | OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR4 | RECQL 3736/4885HCAR1 27/4885P2RX7 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.